A Multicenter, Phase III, Open-Label, Randomized Study in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia to Evaluate the Benefit of GDC-0199 (ABT-199) Plus Rituximab Compared With Bendamustine Plus Rituximab

Trial Profile

A Multicenter, Phase III, Open-Label, Randomized Study in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia to Evaluate the Benefit of GDC-0199 (ABT-199) Plus Rituximab Compared With Bendamustine Plus Rituximab

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Sep 2017

At a glance

  • Drugs Venetoclax (Primary) ; Bendamustine; Rituximab
  • Indications Chronic lymphocytic leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms MURANO
  • Sponsors Roche
  • Most Recent Events

    • 19 Sep 2017 According to an AbbVie media release, full data from this study will support regulatory submissions for venetoclax in combination with Rituxan therapy in R/R CLL, and will be presented at an upcoming medical conference. An independent data monitoring committee has reviewed this study and made the recommendation to unblind the trial based on the positive results.
    • 18 Sep 2017 According to a Genentech media release, data from the study will be submitted to health authorities and presented at an upcoming medical meeting.
    • 18 Sep 2017 Results published in a Genentech media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top